Nicholas Investment Partners’s Nektar Therapeutics NKTR Stock Holding History

Nicholas Investment Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,310	Closed	-$3.32M	–	267
2017 Q2	$3.32M	Buy	+11,310	New	+$3.27M	0.23%	153
2014 Q3	–	Sell	-15,782	Closed	-$3.04M	–	313
2014 Q2	$3.04M	Sell	15,782 -4,970	-24%	-$879K	0.18%	193
2014 Q1	$3.77M	Buy	20,752 +3,102	+18%	+$614K	0.31%	98
2013 Q4	$3M	Sell	17,650 -375	-2%	-$60.5K	0.23%	113
2013 Q3	$2.82M	Sell	18,025 -476	-3%	-$88K	0.23%	130
2013 Q2	$3.21M	Buy	+18,501	New	+$2.84M	0.3%	78

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nicholas Investment Partners's NKTR Position: Q3 2017 in Review

Nicholas Investment Partners sold out of Nektar Therapeutics (NKTR) in Q3 2017, closing a stake of 11,310 shares — an estimated $3.32M sold.

Nicholas Investment Partners first reported a position in NKTR in Q2 2013 and held it in 6 quarters. The position peaked at $3.77M in Q1 2014. 203 funds tracked by Wall St. Rank hold NKTR as of Q3 2017.

Nicholas Investment Partners reported no remaining Nektar Therapeutics position as of Q3 2017 after selling out during the quarter.
Nicholas Investment Partners sold 11,310 Nektar Therapeutics shares in Q3 2017, an estimated $3.32M.
Nicholas Investment Partners first reported a position in Nektar Therapeutics in Q2 2013 and held it in 6 quarters.
Nicholas Investment Partners's Nektar Therapeutics position peaked at $3.77M in Q1 2014.
203 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2017.

Based on Nicholas Investment Partners's 13F filing for Q3 2017, filed 13 Nov 2017.